Schwartz, Gary K.

Tumour exosome integrins determine organotropic metastasis

Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature

Extracellular vesicles in diseaseCancer Cells and Metastasis

Cited by 5,101

Guidelines for the use and interpretation of assays for monitoring autophagy

Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 3,996

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,081

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 759

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 735

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies

Cited by 399

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 366

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 260

Bryostatin-1: A novel PKC inhibitor in clinical development

Kortmansky, J., & Schwartz, G. K. (2003) · Cancer Investigation

Protein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancer

Cited by 183

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 163

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 142

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.

Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 129

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 95

Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets

Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 86

Treatment of growing teratoma syndrome

Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G. (2009) · New England Journal of Medicine

Teratomas and Epidermoid CystsTesticular diseases and treatments

Cited by 82

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., et al. (2021) · Cancer Discovery

Computational Drug Discovery MethodsCancer Genomics and Diagnostics

Cited by 51

Exploring Generative Artificial Intelligence-Assisted Medical Education: Assessing Case-Based Learning for Medical Students

Sauder, M., Tritsch, T., Rajput, V., Schwartz, G., & Shoja, M. M. (2024) · Cureus

Artificial Intelligence in Healthcare and EducationArtificial Intelligence in Education

Cited by 41

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., et al. (2024) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 21

A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101

Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology

Head and Neck Cancer StudiesPARP inhibition in cancer therapy

Cited by 20

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Gounder, M. M., Bauer, T. M., Schwartz, G. K., LoRusso, P., Kumar, P., Kato, K., Tao, B., Hong, Y., Patel, P., & Hong, D. (2020) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 19

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients

Berenson, J. R., Kim, C., Bujarski, S., To, J., Spektor, T. M., Martinez, D., Turner, C., Ghermezi, M., Eades, B. M., Swift, R. A., et al. (2022) · Hematological Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 9

Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth

Rothman, J. H., Surriga, O., de Stanchina, E., Vasudeva, S. D., & Schwartz, G. K. (2017) · Cancer Gene Therapy

RNA Interference and Gene DeliveryMelanoma and MAPK Pathways

Cited by 4

Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.

Ashruf, O., Mushtaq, A., Lin, C. (.-T., Volk, M., Orozco, Z., Hundal, J., Safdar, A., Thompson, C., Karimi, S., Jain, A. G., et al. (2025) · Journal of Clinical Oncology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 4